FDA Approves Toripalimab for Advanced Nasopharyngeal Cancer
Adding toripalimab (Loqtorzi) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
Related Articles
Breastcancer.org – Breast Cancer Information and Support
We are your go-to resource for clear, reliable, accurate, and up-to-date breast cancer information as well as community support.
Pacritinib and Momelotinib Display Positive Real-World Impact on Anemia and Transfusion Needs in Myelofibrosis
Pacritinib and momelotinib both demonstrated favorable real-world effects on anemia and transfusion requirements among patients with myelofibrosis.
OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
What You Should Know About Alcohol Consumption and Cancer Risk | Dana-Farber Cancer Institute
Discover the connection between alcohol consumption and elevated cancer risk.
DCEG’s Role in the Federal Cervical Cancer Collaborative
The Federal Cervical Cancer Collaborative (FCCC) is a multi-year effort to control cervical cancer across safety-net settings of care in the U.S. The FCCC is…
Self-Exams
Examine your skin head-to-toe every month. Self-exams are a simple, powerful way to detect skin cancer early. It could save your life. Learn how.
ASCO Journals Editorial Fellowship | American Society of Clinical Oncology
The ASCO Journals Editorial Fellowship is designed to introduce oncology fellows (or their local equivalent) to the peer review, editing, and publishing of medical research…
Novel CD4+ Donor Lymphocyte Therapy Shows Promising Remission Rates in High-Risk Myeloid Malignancie | Blood Cancers Today
CD4+ MMUDLI treatment achieved complete remission rates of more than 50% in treatment-refractory myelodysplastic syndrome.
